Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ryan Croft

Physician Assistant, Medical Forest Grove, OR Physician Assistant

NPI 1588328314 CMS profile 11271508

1909 Mountain View Ln Ste 200, Forest Grove, OR 97116

Open in the dashboard

General payments

$2,898

58 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Croft of Forest Grove, OR is reported in the CMS Open Payments database as having received $2,898 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $226 9
2024 General $1,686 24
2023 General $613 12
2022 General $373 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Croft
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ryan Croft were reported at $226. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ryan Croft Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $373 $185 $55–$649 $149
2023 $613 $199 $58–$717 $160
2024 $1,686 $206 $62–$740 $164
2025 $226 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $1,454 17 payments
  2. AstraZeneca Pharmaceuticals LP $285 10 payments
  3. Beta Bionics, Inc. $210 3 payments
  4. Dexcom, Inc. $193 4 payments
  5. GlaxoSmithKline, LLC. $158 2 payments
  6. Edwards Lifesciences Corporation $154 1 payment
  7. Novo Nordisk Inc $138 8 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $135 3 payments
  9. Tandem Diabetes Care, Inc. $37 2 payments
  10. Mitsubishi Tanabe Pharma America, Inc. $25 1 payment
  11. Other $110 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,938 55 payments
  2. Travel and Lodging $961 3 payments
Products named General payments · program years 2022–2025
  1. MINIMED 780G $1,360 13 payments
  2. Dexcom G6 Transmitter $193 4 payments
  3. BREZTRI $177 3 payments
  4. iLet Bionic Pancreas Automated insulin delivery system $145 1 payment
  5. iLet Bionic Pancreas Automated insulin delivery system $145 1 payment
  6. iLet Bionic Pancreas Automated insulin delivery system $145 1 payment
  7. Kerendia $135 3 payments
  8. SHINGRIX $125 1 payment
  9. FARXIGA $109 6 payments
  10. Ozempic $70 4 payments
  11. Other $753 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

6,155

Median for Physician Assistant: 241

Drug cost

$745,619

Median for Physician Assistant: $4,110

Branded share of claims

22.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 94 $119,142
Jardiance Empagliflozin Brand 82 $99,321
Farxiga Dapagliflozin Propanediol Brand 80 $94,396
Eliquis Apixaban Brand 82 $84,215
Januvia Sitagliptin Phosphate Brand 32 $34,998
Trulicity Dulaglutide Brand 22 $33,583
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 34 $26,858
Vraylar Cariprazine Hcl Brand 14 $26,647
Incruse Ellipta Umeclidinium Bromide Brand 28 $20,431
Invega Sustenna Paliperidone Palmitate Brand 11 $19,755

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$85,091

Of which drugs: $19,374

Medicare patients

267

Average age 73

Services billed

3,903

152 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 40%
Heart failure 31%
Chronic kidney disease 30%
Depression 26%
Ischemic heart disease 23%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 840 $16,743
Vaccine for influenza for injection into muscle 90662 Office 12 12 $863
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 68 $317
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 1,000 $95

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $37
$37 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $33
$33 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $22
$22 — —
SUBLOCADE
  • Indivior Inc. $21
$21 — —
Repatha
  • Amgen Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record